Results 271 to 280 of about 93,898 (384)

Real-World Effectiveness and Safety of Mepolizumab in Severe Eosinophilic Asthma: Insights From the Korean Severe Asthma Registry (KoSAR). [PDF]

Allergy Asthma Immunol Res
Park SY, Lee D, Kim JH, Lee Y, Ban GY, Sim DW, Kwon JW, Kim SR, Song WJ, Park HW, Chang YS, Koh YI, Lee BJ, Park HS, Cho YS, Kim SH.   +15 more
europepmc   +1 more source

Responses to Biological Therapy in Severe Eosinophilic Asthma

, 2019
M J Alvarez-Puebla, Esozia Arroabarren, M J Zavala, A Corcuera, A Olaguibel, José M. Rivera   +5 more
openalex   +1 more source

Assessment of the long‐term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma

Journal of Allergy and Clinical Immunology, 2019
S. Khatri, W. Moore, P. Gibson, R. Leigh, A. Bourdin, J. Maspero, M. Barros, R. Buhl, P. Howarth, F. Albers, E. Bradford, M. Gilson, R. Price, S. Yancey, H. Ortega   +14 more
semanticscholar   +1 more source

Early and Sustained Response to Benralizumab in Severe, Eosinophilic Asthma: A Real-World Observational Study. [PDF]

J Asthma Allergy
Stolz D, Schuoler C, Charbonnier F, Bridevaux PO, Jandus P, Leuppi JD, Pavlov N, Piecyk A, Rothe T.   +8 more
europepmc   +1 more source

Emerging Risk: Intranasal Tin Exacerbates Allergic Rhinitis in Humans and Mice

Allergy, EarlyView.
Delgama A. S. M. Nishadhi, Shogo Sumiya, Akira Tazaki, Takumi Kagawa, Mohamed Abdelmoneim, Masafumi Sakashita, Kazuhiro Ogi, Shigeharu Fujieda, Shinichi Iwasaki, Masashi Kato   +9 more
wiley   +1 more source

Stellate Ganglion Block and Bilateral Sympathectomy for Recurrent Coronary Vasospasm Secondary to Severe Eosinophilic Asthma. [PDF]

JACC Case Rep
Wu KY, Mao R, Butler C, Gouda P, Alhulaimi N, Parab R, Dicken BJ, Khandekar S, Graham M, Bainey KR.   +9 more
europepmc   +1 more source

Forced oscillatory technique R5-19 values correlate with spirometry FEV1/FVC in severe eosinophilic asthma. An observational, prospective, cohort study [PDF]

Claudio Tirelli, Elena Maria Parazzini, Lucia Sacchi, Giovanni Carone, Francesca Pescol, Sara Maggioni, Luca Alessandro Belmonte, Cristina Albrici, Silvia Contino, Beatrice Re, Benedetta Mosole, Michele Mondoni, Stefano Centanni   +12 more
openalex   +1 more source

Early and Sustained Asthma Control and Remission in Real‐World Patients With Severe Eosinophilic Asthma Treated With Benralizumab: XALOC‐2

Clinical &Experimental Allergy, EarlyView.
Real‐world patients with severe eosinophilic asthma treated with benralizumab showed early and sustained improvements in symptoms. Clinically meaningful improvements began as early as one week after benralizumab initiation, regardless of previous biologic use, and further improved over the following year.
Erika Penz, Thomas Rothe, Lieven Dupont, Trung N. Tran, Andrew Menzies‐Gow, Anat Shavit, David Cohen, Tanja Plate, Sheena Kayaniyil, An Herreman, Claudio Schuoler, Benjamin Emmanuel, Marek Lommatzsch   +12 more
wiley   +1 more source

Long-Term Clinical Remission on Benralizumab Treatment in Severe Eosinophilic Asthma: A Four-Year Real-Life Study. [PDF]

J Clin Med
Quarato CMI, Tondo P, Lacedonia D, Soccio P, Pescatore D, Baccellieri ML, Lepore G, Foschino Barbaro MP, Scioscia G.   +8 more
europepmc   +1 more source

Dupilumab Dampens Mucosal Type 2 Response During Acetylsalicylic Acid Challenge in N‐ERD Patients

Clinical &Experimental Allergy, EarlyView.
Dupilumab therapy reduced elevated type 2 cytokine responses post‐ASA provocation in N‐ERD patients, independent of ASA tolerance, and revealed novel mechanistic insights by modulating acute type 2 immunity. Transcriptomic analysis showed concurrent downregulation of lipid and peroxisome pathways during ASA challenge in N‐ERD patients after 24 weeks of
Julia Eckl‐Dorna, Christina Morgenstern, Katharina Poglitsch, Tamara Arnoldner, Katharina Gangl, Tina J. Bartosik, Nicholas J. Campion, Aldine Tu, Victoria Stanek, Sven Schneider, Christine Bangert   +10 more
wiley   +1 more source